Caris Life Sciences
Caris Life Sciences Inc is an American molecular science and biotechnology company advancing precision medicine through comprehensive genomic profiling. The company provides molecular profiling services, including whole exome and whole transcriptome sequencing, paired with artificial intelligence analytics to guide personalized cancer treatment. Main revenue drivers consist of clinical diagnostic testing fees for tissue and liquid biopsies billed to insurance providers and health systems, alongside biopharmaceutical data licensing fees. Caris Life Sciences serves oncologists, hospital networks, clinical research institutes, and pharmaceutical development partners across the United States and global markets. The company holds a pioneer position in multi-cancer molecular profiling and AI-driven precision oncology data. Headquartered in Irving, Texas, Caris Life Sciences operates as a private company.
5 of the funds FundTelligence covers report a position in Caris Life Sciences.
- Legal name
- Caris Life Sciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Cancer Profiling, Molecular Diagnostics, Precision Medicine & Genomics, Artificial Intelligence, Clinical Data & Precision Medicine, Healthcare
Funds holding Caris Life Sciences
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.46 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.34 % (full portfolio disclosed, October 2026)
- JPM US Small Cap Growth Fund — JPM · 0.32 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)